Assessing the cardiovascular safety of novel compounds is an important clinical drug development objective for drugs with preclinical cardiovascular safety signals and agents for which a cardiovascular class effect is suspected. Consequently, for most compounds, regulatory authorities still expect to see a Thorough QT (TQT) study according to ICH-E14. PRA Health Sciences (PRA) provides the expertise you need to optimize study design and execution for TQT studies and ECG assessments during early clinical development and in clinical pharmacology studies.

Register to download

ECG Assessment During TQT and Early Clinical Studies